Screener
BridgeBio Pharma BBIO Total Cost of Revenue
Total Cost of Revenue at other companies
Segments
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:CostOfRevenue.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Cost of revenues: | ||
| Cost of goods sold | 7,732 | 2,034 |
| Cost of license, services, and royalty revenue | 2,207 | 605 |
| Total cost of revenues | 9,939 | 2,639 |
| Research and development | 126,636 | 111,431 |
| Selling, general and administrative | 163,896 | 106,365 |
| Restructuring, impairment, and related charges | — | 570 |
| Total operating costs and expenses | 300,471 | 221,005 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's total cost of revenue?
- BridgeBio Pharma (BBIO) reported total cost of revenue of $9.94M in Q1 2026.
- How has BridgeBio Pharma's total cost of revenue changed year-over-year?
- BridgeBio Pharma's total cost of revenue increased by 276.6% year-over-year, from $2.64M to $9.94M.
- What is the long-term trend for BridgeBio Pharma's total cost of revenue?
- Over 4 years (2021 to 2025), BridgeBio Pharma's total cost of revenue has grown at a 66.4% compound annual growth rate (CAGR), from $2.74M to $20.96M.
- What does total cost of revenue mean?
- The aggregate of all direct costs attributable to producing goods and delivering services that generated the company's revenue, including materials, labor, and overhead.
Ask your AI about BridgeBio Pharma's total cost of revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude